Trial reportCirculation2016
Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.
Open access · bronzeAbstract readClinical TrialLetter
In one paragraph
Trial report in Circulation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.Antimicrobial agents and chemotherapy · 2017Trial
- Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review.Frontiers in pharmacology · 2025Review
- MONSTROUS: a web-based chemical-transporter interaction profiler.Frontiers in pharmacology · 2025Article
- Drug-Drug Interactions Between HIV Antivirals and Concomitant Drugs in HIV Patients: What We Know and What We Need to Know.Pharmaceutics · 2024Review
- Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy-Update 2022: Systematic Review.Pharmaceutics · 2023Review
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2021Article
- Cobicistat: A case of mislabelled drug-drug interaction risk?British journal of clinical pharmacology · 2020Article
- Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).Drugs · 2019Review
- Cilastatin protects against imipenem-induced nephrotoxicityActa pharmaceutica Sinica. B · 2019Article
- Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.Antimicrobial agents and chemotherapy · 2018Article
- Response to "Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation".CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Lori A GordonFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Parag KumarFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.). Parag.kumar@nih.gov.
Kristina M BrooksFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Anela KelloggFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Maryellen McManusFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Raul M AlfaroFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Khanh NghiemFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Jomy M GeorgeFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Jay LozierFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Scott R PenzakFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Colleen HadiganFrom Clinical Pharmacokinetics Research Unit, Clinical Center Pharmacy Department, (L.A.G., R.K., K.M.B., R.M.A., J.M.G., S.R.P.), Clinical Research Center, Clinical Center Department of Laboratory Medicine (K.N., J.L.), National Institute of Allergy and Infectious Diseases (C.H.), National Institutes of Health, Bethesda, MD; Xavier University of Louisiana, College of Pharmacy, New Orleans (L.A.G.); Leidos Biomedical Research, Inc, Frederick, MD (A.K.); Parker Tide Corporation, Washington, DC (M.M.); and University of North Texas System College of Pharmacy, Department of Pharmacotherapy, Fort Worth (S.R.P.).
Xavier University of Louisiana · USLeidos (United States) · USParker Hannifin (United States) · USLeidos Biomedical Research Inc. (United States)Louisiana Christian University · US
Funding
Xavier's RCMI Cancer Research ProgramG12MD007595 · NIMHD · XAVIER UNIVERSITY OF LOUISIANA · PI D'AMOUR, GENE, WANG, GUANGDI · 2012 to 2018
$15.7MThe Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and PharZIACL006005 · CLC · CLINICAL CENTER · PI GEORGE, JOMY · 2014 to 2021
$0kEndothelial, Platelet, & Coagulation Factor Abnormalities in Abnormal HemostasisZIACL080014 · CLC · CLINICAL CENTER · PI LOZIER, JAY · 2009 to 2017
$0kIntramural NIH HHS Z99 AI999999Intramural NIH HHS Z99 CL999999Intramural NIH HHS ZIA CL006005NIMHD NIH HHS G12 MD007595
Abstract
PubMed holds no abstract for this paper.
Indexed as
Administration, OralAnti-HIV AgentsAntithrombinsBlood CoagulationCobicistatCytochrome P-450 CYP3A InhibitorsDabigatranDrug InteractionsHealthy VolunteersHumansThrombin TimeAnti-HIV AgentsAntithrombinsCobicistatCytochrome P-450 CYP3A InhibitorsDabigatrananticoagulantsantiretroviralcobicistatdabigatrandrug-drug interactionpharmacodynamicspharmacokineticsthrombin time
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.